Description: Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, autoimmune/immunology, neurology, respiratory, and other. In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services. Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Home Page: selvita.com
Hexagon
Kraków,
30-394
Poland
Phone:
48 123 00 50 01
Officers
Name | Title |
---|---|
Mr. Boguslaw Stanislaw Sieczkowski M.B.A. | Chairman of Management Board & CEO |
Dr. Milosz Kazimierz Gruca Ph.D. | Chief Commercial Officer, Executive VP & Vice President of Management Board |
Mr. Dariusz Tomasz Kurdas | CFO & Member of the Management Board |
Dr. Miroslawa Monika Zydron Ph.D. | COO & Member of the Management Board |
Mr. Dawid Patryk Radziszewski | General Counsel & Member of the Management Board |
Dr. Adrijana Vinter | Global Head of Drug Discovery & Member of the Management Board |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 17.7681 |
Price-to-Book MRQ: | 3.0341 |
Price-to-Sales TTM: | 0.693 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 886 |